Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori
Abstract Background Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection sta...
Main Authors: | Seung Won Ra, Marc A. Sze, Eun Chong Lee, Sheena Tam, Yeni Oh, Nick Fishbane, Gerard J. Criner, Prescott G. Woodruff, Stephen C. Lazarus, Richard Albert, John E. Connett, Meilan K. Han, Fernando J. Martinez, Shawn D. Aaron, Robert M. Reed, S. F. Paul Man, Don D. Sin, on behalf of the Canadian Respiratory Research Network |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-017-0594-x |
Similar Items
-
Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations
by: Ester Cuevas, et al.
Published: (2023-07-01) -
Favorable Response to Long-Term Azithromycin Therapy in Bronchiectasis Patients with Chronic Airflow Obstruction Compared to Chronic Obstructive Pulmonary Disease Patients without Bronchiectasis
by: Choi Y, et al.
Published: (2021-03-01) -
Sputum-Rheology-Based Strategy for Guiding Azithromycin Prescription in COPD Patients with Frequent Exacerbations: A Randomized, Controlled Study (“COPD CARhE”)
by: Jeremy Charriot, et al.
Published: (2023-03-01) -
The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies
by: Kui Li, et al.
Published: (2022-10-01) -
LONG-TERM AZITHROMYCIN TREATMENT IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: Vanya Kostadinova, et al.
Published: (2020-07-01)